The prevalence of CVI among Italian women is over 30%, with a significant increase after 50 years of age, reaching 50% among those over 50.
This disorder can lead to:
-
Discomfort and heaviness
-
Edema
-
Varicose veins
-
Telangiectasias
-
"Restless Legs" (nighttime sensation)
-
Lower limb pain
-
Skin hypopigmentation
-
Lipodermatosclerosis (inflammation and thickening of subcutaneous fat)
-
Venous ulcers
There are some functional components in nutraceuticals that can provide essential support to alleviate these situations.
Troxerutin acts as a vasoprotector useful in these cases.
It is a semi-synthetic flavonoid belonging to the rutin family, widely used for the treatment of venous circulation disorders, especially in the legs.
It is known for its phleboprotective, anti-inflammatory, and anti-edematous properties.
It acts by strengthening blood vessel walls and reducing capillary permeability, thus helping to limit fluid leakage into tissues.
Furthermore, it inhibits platelet aggregation and improves blood viscosity, promoting better circulation.
Some clinical studies have shown that regular use of troxerutin can significantly reduce symptoms such as swelling, pain, and a feeling of heaviness in the lower limbs.
Its antioxidant action also helps to protect the endothelium from oxidative stress, a condition often associated with chronic venous insufficiency. It is well absorbed orally and has good tolerability. It is useful both for prevention and in the presence of established disorders.
Troxerutin is a key ingredient in Plas Gambe Leggere, the supplement formulated to support microcirculation function and leg lightness.
Chronic Venous Insufficiency (CVI), also known as Chronic Venous Disease (CVD), is a pathology characterized by a deficit in venous return from the lower limbs to the heart, particularly evident during prolonged standing. This condition is determined by a functional alteration of the venous valves or reduced venous wall tone, resulting in blood stasis and increased distal venous pressure.
